Skip to main content
. 2020 Jan 11;2020:9505312. doi: 10.1155/2020/9505312

Figure 3.

Figure 3

Relative expression levels of serum miR-1291 and levels of serum CCL17 and anti-BP180 in the active stage (baseline) and disease control stage of the 13 BP patients. As compared with baseline values, significant reductions in the disease control stage were obtained for (a) relative expression levels of serum miR-1291 (P = 0.006), (b) serum CCL17 levels (P = 0.002), and (c) serum anti-BP180 levels (n = 10, P = 0.004).